Pharmacokinetics of hydroxycamptothecin nanosuspensions in rats

Pharmazie

Volumn 66, Issue 7, 2011, Pages 547-548

  Wang, Lei ^a   Hua, Hai Ying ^a   Liu, Wei Jing ^a   Zhao, Yong Xing ^a   Zhang, Zhen Zhong ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN; 10-HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CENTRIFUGATION; CONTROLLED STUDY; DRUG CLEARANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MEDICAL PARAMETERS; NANOSUSPENSION; NONHUMAN; RAT; SARCOMA; SUSPENSION; TOTAL BODY CLEARANCE; ANIMAL; CHEMISTRY; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CAMPTOTHECIN; CHEMISTRY, PHARMACEUTICAL; HALF-LIFE; INJECTIONS, INTRAVENOUS; NANOPARTICLES; RATS; RATS, WISTAR; SUSPENSIONS;

EID: 80051916381     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2011.0400     Document Type: Article

References (11)

1. Burke TG, Mi Z (1993) Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal Biochem 212: 285-287. (Pubitemid 23219487)
2. Hertzberg RP, Caranfa MJ, Holden KG, Jakas DR, Gallagher G, Mattern MR, Mong SM, Bartus JO, Johnson RK, Kingsbury WD (1989) Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32: 715-720.
3. Jacobs C, Müller RH (2002) Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res 19: 189-194. (Pubitemid 34165405)
4. Keck CM, Müller RH (2006) Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 62: 3-16. (Pubitemid 41736019)
5. Moschwitzer J, Achleitner G, Pomper H, Müller RH (2004) Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm 58: 615-619. (Pubitemid 39297108)
6. Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G (2002) Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci 16: 53-61. (Pubitemid 34756782)
7. Rabinow BE (2004) Nanosuspensions in drug delivery. Nat Rev Drug Discov 3: 785-796.
8. Wani MC, Ronman PE, Lindley JT,Wall ME (1980) Plant antitumor agents 18. Synthesis and biological activity of camptothecin analogues. J Med Chem 23: 554-560. (Pubitemid 10153550)
9. Wong J, Brugger A, Khare A, Chaubal M, Papadopoulos P, Rabinow B, Kipp J, Ning J (2008) Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv Drug Deliv Rev 60: 939-954.
10. Zhang L, Li S, Liao H, Jiang WQ, Guan ZZ (2001) Phase I Trial of Pharmacokinetics and Human Tolerability to 10-Hydroxycamptothecin in Patients with Advanced Malignancy. Ai Zheng 20: 1391-1395.
11. Zhao YX, Hua HY, Chang M, Liu WJ, Zhao Y, Liu HM (2010) Preparation and cytotoxic activity of hydroxycamptothecin nanosuspensions. Int J Pharm 392: 64-71.